Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry
Open Access
- 28 April 2025
- journal article
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (6) , e00844
Abstract
INTRODUCTION: Despite being underappreciated, pruritus and fatigue are not uncommon in metabolic dysfunction-associated steatotic liver disease (MASLD). In this prospective registry-based study, we sought to evaluate the prevalence, predictors, and impact of these symptoms on patient-reported outcomes (PROs) in patients with MASLD from Türkiye, a country with one of the highest burdens of MASLD globally. METHODS: A total of 1,874 Turkish patients from the Global Liver Registry were included. Significant pruritus and fatigue were defined using the Chronic Liver Disease Questionnaire-nonalcoholic steatohepatitis and the Functional Assessment of Chronic Illness Therapy-Fatigue, respectively. PROs were assessed using the Chronic Liver Disease Questionnaire-nonalcoholic steatohepatitis, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Work Productivity and Activity Impairment: Specific Health Problem questionnaire. RESULTS: The prevalence of significant pruritus and fatigue was 37% and 33%, respectively. Both symptoms were significantly associated with female sex, type 2 diabetes, depression, abdominal pain, and lack of regular exercise. Patients with these symptoms had significantly worse PROs, with impairments up to 31% (all P < 0.0001). Over 1–2 years, symptoms persisted in 47%–52% of patients with baseline pruritus and 33%−39% with baseline fatigue. Independent predictors of a higher likelihood of resolution of pruritus included the absence of fatigue at baseline and the lack of abdominal pain, with odds ratios of 0.36 (95% confidence interval: 0.22−0.59) and 0.60 (95% confidence interval: 0.39−0.91), respectively (both P < 0.05). DISCUSSION: Pruritus and fatigue are common in MASLD, significantly impairing PROs and often persisting over time. Regular assessment and management are essential to improve patients' well-being and functioning.Keywords
Funding Information
- This study was partially funded by the Global NASH Council and the Center for Outcomes Research in Liver Disease (0000)
This publication has 34 references indexed in Scilit:
- Non-alcoholic fatty liver disease: A growing public health problem in TurkeyTurkish Journal of Gastroenterology, 2019
- Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic SteatohepatitisClinical Gastroenterology and Hepatology, 2019
- Fatigue interventions in long term, physical health conditions: A scoping review of systematic reviewsPLOS ONE, 2018
- Prevalence of pruritus in patients with chronic liver disease: A multicenter studyHepatology Research, 2017
- Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical managementJournal of Hepatology, 2015
- Patients' preferences and health utility assessment with SF‐6D and EQ‐5D in patients with chronic hepatitis C treated with sofosbuvir regimensAlimentary Pharmacology & Therapeutics, 2014
- Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 yearsGut, 2010
- Building a Measure of Fatigue: The Functional Assessment of Chronic Illness Therapy Fatigue ScalePM&R, 2010
- Fatigue in Liver Disease: Pathophysiology and Clinical ManagementCanadian Journal of Gastroenterology and Hepatology, 2006
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993